Transforming Cancer Care Today and Tomorrow

With an estimated 28 million new cancer diagnoses expected worldwide each year by 20401, we know we must strive to maximize the impact of our treatments and pioneer novel medicines. Our work in oncology is driven by the belief that we can improve the futures of people living with cancer. Our science of cancer is opening up new possibilities and sparking discovery to explore the full potential of promising mechanisms.

   

Our Products

BAVENCIO® (avelumab) Injection 20mg/mL

TEPMETKO® (tepotinib)
 
Learn more

On the EMD Group website

Learn about our key disease areas and more: 

Our Vibrant Thoughts Blog

More on EMDGroup.com

Oncology News

View All News

  1. Press Releases

    Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant ...

    Following Priority Review, the China National Medical Products Administration has approved pimicotinib for the treatment of adult patients with symptomatic TGCT.

    2025/12/22

  2. Press Releases

    Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued ...

    The company today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor

    2025/10/17

  3. Press Releases

    Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy ...

    The company today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib

    2025/05/28

Footnotes

1 American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed May 3, 2021.